ImmuCell Corp
NASDAQ:ICCC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.56
7.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ImmuCell Corp
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 60 full-time employees. The firm is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. The company manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. The company expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The firm is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 60 full-time employees. The firm is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. The company manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. The company expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The firm is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
